Vergelijking

Lanreotid vs. Teduglutid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

108736-35-2

197922-42-2

Molecuulmassa

1096.34 g/mol

3752.13 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Teduglutid

Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Lanreotid	Teduglutid
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Lanreotid

Volledige vermelding →

Teduglutid

Volledige vermelding →

Frequently asked questions

What is the difference between Lanreotid and Teduglutid?: Lanreotid is classified as "Onderzoek (overig)", while Teduglutid is classified as "Onderzoek (overig)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lanreotid or Teduglutid?: The highest available evidence level is "Humane RCT" for Lanreotid and "Humane RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lanreotid and Teduglutid in Germany and the United States?: Duitsland: Lanreotid — Op recept, Teduglutid — Op recept. Verenigde Staten: Lanreotid — Op recept, Teduglutid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Lanreotid

Teduglutid

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Lanreotid and Teduglutid?

Lanreotid is classified as "Onderzoek (overig)", while Teduglutid is classified as "Onderzoek (overig)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lanreotid or Teduglutid?

The highest available evidence level is "Humane RCT" for Lanreotid and "Humane RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lanreotid and Teduglutid in Germany and the United States?

Duitsland: Lanreotid — Op recept, Teduglutid — Op recept. Verenigde Staten: Lanreotid — Op recept, Teduglutid — Op recept. These are factual summaries with source and review date on the individual pages.